Journal of Cancer Research and Clinical Oncology

, Volume 141, Issue 7, pp 1195–1203 | Cite as

Epigenetically silenced long noncoding-SRHC promotes proliferation of hepatocellular carcinoma

Original Article – Cancer Research



To investigate the expression of SRHC and the role of SRHC in the pathogenesis of hepatocellular carcinoma (HCC).


We analyzed HCC samples and matched non-tumor liver tissues (controls) collected from 81 patients who underwent hepatectomy in Shanghai, China. The expression levels of SRHC were determined by quantitative reverse-transcription polymerase chain reaction. Statistical analyses were used to associate the levels of SRHC with tumor features and patient outcomes.


We found that a lower SRHC expression level was significantly more frequent in tissues with a high serum a-fetoprotein level (positive, >20 µg/L, P = 0.004) and a low degree of differentiated tumors (poorly differentiated, P = 0.017). Furthermore, we found that the promoter region of SRHC contains a CpG-rich island and that SRHC is down-regulated in tumors by DNA methylation.


Here, we identified a new long noncoding RNA designated as SRHC that is capable of inhibiting cancer proliferation and is down-regulated in tumors at least partly by DNA methylation.


Hepatocellular carcinoma Splicing SRHC LncRNA Methylation 



The authors acknowledge Shuai Li for his detailed bioinformatics analysis of SRHC.

Conflict of interest

We declare that we have no conflict of interest.

Supplementary material

432_2014_1871_MOESM1_ESM.tif (1.1 mb)
Supplementary material 1 (TIFF 1082 kb)
432_2014_1871_MOESM2_ESM.tif (727 kb)
Supplementary material 2 (TIFF 727 kb)
432_2014_1871_MOESM3_ESM.docx (15 kb)
Supplementary material 3 (DOCX 14 kb)


  1. Block TM, Mehta AS, Fimmel CJ, Jordan R (2003) Molecular viral oncology of hepatocellular carcinoma. Oncogene 22(33):5093–5107. doi: 10.1038/sj.onc.1206557 CrossRefPubMedGoogle Scholar
  2. Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA, Wang XW (2006) Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 10(2):99–111. doi: 10.1016/j.ccr.2006.06.016 CrossRefPubMedGoogle Scholar
  3. Chen CJ, Chen DS (2002) Interaction of hepatitis B virus, chemical carcinogen, and genetic susceptibility: multistage hepatocarcinogenesis with multifactorial etiology. Hepatology 36(5):1046–1049. doi: 10.1053/jhep.2002.37084 CrossRefPubMedGoogle Scholar
  4. Du Y, Kong G, You X, Zhang S, Zhang T, Gao Y, Zhang X (2012) Elevation of highly up-regulated in liver cancer (HULC) by hepatitis B virus X protein promotes hepatoma cell proliferation via down-regulating p18. J Biol Chem 287(31):26302–26311. doi: 10.1074/jbc.M112.342113 CrossRefPubMedCentralPubMedGoogle Scholar
  5. Eissmann M, Gutschner T, Hammerle M, Gunther S, Caudron-Herger M, Gross M, Diederichs S (2012) Loss of the abundant nuclear non-coding RNA MALAT1 is compatible with life and development. RNA Biol 9(8):1076–1087. doi: 10.4161/rna.21089 CrossRefPubMedCentralPubMedGoogle Scholar
  6. El-Serag HB (2012) Surveillance for hepatocellular carcinoma: long way to achieve effectiveness. Dig Dis Sci 57(12):3050–3051. doi: 10.1007/s10620-012-2413-z CrossRefPubMedGoogle Scholar
  7. Gonzalez FJ (2008) Regulation of hepatocyte nuclear factor 4 alpha-mediated transcription. Drug Metab Pharmacokinet 23(1):2–7CrossRefPubMedGoogle Scholar
  8. Hayhurst GP, Lee YH, Lambert G, Ward JM, Gonzalez FJ (2001) Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis. Mol Cell Biol 21(4):1393–1403. doi: 10.1128/MCB.21.4.1393-1403.2001 CrossRefPubMedCentralPubMedGoogle Scholar
  9. Huang JF, Guo YJ, Zhao CX, Yuan SX, Wang Y, Tang GN, Sun SH (2013) Hepatitis B virus X protein (HBx)-related long noncoding RNA (lncRNA) down-regulated expression by HBx (Dreh) inhibits hepatocellular carcinoma metastasis by targeting the intermediate filament protein vimentin. Hepatology 57(5):1882–1892. doi: 10.1002/hep.26195 CrossRefPubMedGoogle Scholar
  10. Inoue Y, Peters LL, Yim SH, Inoue J, Gonzalez FJ (2006a) Role of hepatocyte nuclear factor 4alpha in control of blood coagulation factor gene expression. J Mol Med (Berl) 84(4):334–344. doi: 10.1007/s00109-005-0013-5 CrossRefGoogle Scholar
  11. Inoue Y, Yu AM, Yim SH, Ma X, Krausz KW, Inoue J, Gonzalez FJ (2006b) Regulation of bile acid biosynthesis by hepatocyte nuclear factor 4alpha. J Lipid Res 47(1):215–227. doi: 10.1194/jlr.M500430-JLR200 CrossRefPubMedCentralPubMedGoogle Scholar
  12. Lagisetti C, Palacios G, Goronga T, Freeman B, Caufield W, Webb TR (2013) Optimization of antitumor modulators of pre-mRNA splicing. J Med Chem 56(24):10033–10044. doi: 10.1021/jm401370h CrossRefPubMedCentralPubMedGoogle Scholar
  13. Lan SH, Wu SY, Zuchini R, Lin XZ, Su IJ, Tsai TF, Liu HS (2014) Autophagy suppresses tumorigenesis of hepatitis B virus-associated hepatocellular carcinoma through degradation of microRNA-224. Hepatology 59(2):505–517. doi: 10.1002/hep.26659 CrossRefPubMedCentralPubMedGoogle Scholar
  14. Lazarevich NL, Cheremnova OA, Varga EV, Ovchinnikov DA, Kudrjavtseva EI, Morozova OV, Duncan SA (2004) Progression of HCC in mice is associated with a downregulation in the expression of hepatocyte nuclear factors. Hepatology 39(4):1038–1047. doi: 10.1002/hep.20155 CrossRefPubMedGoogle Scholar
  15. Liu Y, Zhang JB, Qin Y, Wang W, Wei L, Teng Y, Xie Y (2013) PROX1 promotes hepatocellular carcinoma metastasis by way of up-regulating hypoxia-inducible factor 1alpha expression and protein stability. Hepatology 58(2):692–705. doi: 10.1002/hep.26398 CrossRefPubMedGoogle Scholar
  16. Nagano T, Fraser P (2011) No-nonsense functions for long noncoding RNAs. Cell 145(2):178–181. doi: 10.1016/j.cell.2011.03.014 CrossRefPubMedGoogle Scholar
  17. Ning BF, Ding J, Yin C, Zhong W, Wu K, Zeng X, Xie WF (2010) Hepatocyte nuclear factor 4 alpha suppresses the development of hepatocellular carcinoma. Cancer Res 70(19):7640–7651. doi: 10.1158/0008-5472.CAN-10-0824 CrossRefPubMedGoogle Scholar
  18. Orom UA, Derrien T, Beringer M, Gumireddy K, Gardini A, Bussotti G, Shiekhattar R (2010) Long noncoding RNAs with enhancer-like function in human cells. Cell 143(1):46–58. doi: 10.1016/j.cell.2010.09.001 CrossRefPubMedCentralPubMedGoogle Scholar
  19. Prensner JR, Chinnaiyan AM (2011) The emergence of lncRNAs in cancer biology. Cancer Discov 1(5):391–407. doi: 10.1158/2159-8290.CD-11-0209 CrossRefPubMedCentralPubMedGoogle Scholar
  20. Prensner JR, Iyer MK, Sahu A, Asangani IA, Cao Q, Patel L, Chinnaiyan AM (2013) The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat Genet 45(11):1392–1398. doi: 10.1038/ng.2771 CrossRefPubMedGoogle Scholar
  21. Qureshi IA, Mattick JS, Mehler MF (2010) Long non-coding RNAs in nervous system function and disease. Brain Res 1338:20–35. doi: 10.1016/j.brainres.2010.03.110 CrossRefPubMedGoogle Scholar
  22. Sladek FM (1993) Orphan receptor HNF-4 and liver-specific gene expression. Receptor 3(3):223–232PubMedGoogle Scholar
  23. Sladek FM, Zhong WM, Lai E, Darnell JE Jr (1990) Liver-enriched transcription factor HNF-4 is a novel member of the steroid hormone receptor superfamily. Genes Dev 4(12B):2353–2365CrossRefPubMedGoogle Scholar
  24. Tan YJ (2011) Hepatitis B virus infection and the risk of hepatocellular carcinoma. World J Gastroenterol 17(44):4853–4857. doi: 10.3748/wjg.v17.i44.4853 CrossRefPubMedCentralPubMedGoogle Scholar
  25. Tripathi V, Shen Z, Chakraborty A, Giri S, Freier SM, Wu X, Prasanth KV (2013) Long noncoding RNA MALAT1 controls cell cycle progression by regulating the expression of oncogenic transcription factor B-MYB. PLoS Genet 9(3):e1003368. doi: 10.1371/journal.pgen.1003368 CrossRefPubMedCentralPubMedGoogle Scholar
  26. van Malenstein H, Verslype C, Windmolders P, van Eijsden R, Nevens F, van Pelt J (2012) Characterization of a cell culture model for clinically aggressive hepatocellular carcinoma induced by chronic hypoxia. Cancer Lett 315(2):178–188. doi: 10.1016/j.canlet.2011.09.039 CrossRefPubMedGoogle Scholar
  27. Walesky C, Edwards G, Borude P, Gunewardena S, O’Neil M, Yoo B, Apte U (2013) Hepatocyte nuclear factor 4 alpha deletion promotes diethylnitrosamine-induced hepatocellular carcinoma in rodents. Hepatology 57(6):2480–2490. doi: 10.1002/hep.26251 CrossRefPubMedCentralPubMedGoogle Scholar
  28. Whittaker S, Marais R, Zhu AX (2010) The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 29(36):4989–5005. doi: 10.1038/onc.2010.236 CrossRefPubMedGoogle Scholar
  29. Wilusz JE, Sunwoo H, Spector DL (2009) Long noncoding RNAs: functional surprises from the RNA world. Genes Dev 23(13):1494–1504. doi: 10.1101/gad.1800909 CrossRefPubMedCentralPubMedGoogle Scholar
  30. Xu L, Hui L, Wang S, Gong J, Jin Y, Wang Y, Hu G (2001) Expression profiling suggested a regulatory role of liver-enriched transcription factors in human hepatocellular carcinoma. Cancer Res 61(7):3176–3181PubMedGoogle Scholar
  31. Xu Y, Hu B, Choi AJ, Gopalan B, Lee BH, Kalady MF, Ting AH (2012) Unique DNA methylome profiles in CpG island methylator phenotype colon cancers. Genome Res 22(2):283–291. doi: 10.1101/gr.122788.111 CrossRefPubMedCentralPubMedGoogle Scholar
  32. Yang F, Huo XS, Yuan SX, Zhang L, Zhou WP, Wang F, Sun SH (2013) Repression of the long noncoding RNA-LET by histone deacetylase 3 contributes to hypoxia-mediated metastasis. Mol Cell 49(6):1083–1096. doi: 10.1016/j.molcel.2013.01.010 CrossRefPubMedGoogle Scholar
  33. Zhang L, Yang F, Yuan JH, Yuan SX, Zhou WP, Huo XS, Sun SH (2013) Epigenetic activation of the MiR-200 family contributes to H19-mediated metastasis suppression in hepatocellular carcinoma. Carcinogenesis 34(3):577–586. doi: 10.1093/carcin/bgs381 CrossRefPubMedGoogle Scholar
  34. Zhu Z, Gao X, He Y, Zhao H, Yu Q, Jiang D, Gao Y (2012) An insertion/deletion polymorphism within RERT-lncRNA modulates hepatocellular carcinoma risk. Cancer Res 72(23):6163–6172. doi: 10.1158/0008-5472.CAN-12-0010 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery HospitalSecond Military Medical UniversityShanghaiChina
  2. 2.Department of Medical GeneticsSecond Military Medical UniversityShanghaiChina
  3. 3.Department of Laboratory Medicine, Changhai HospitalSecond Military Medical UniversityShanghaiChina

Personalised recommendations